Is IBM Stock ‘A Place To Hide’ In Volatile Market? PreMarket Prep Crew Talks Big Blue

By Benzinga
Benzinga
Benzinga
April 15, 2022 Updated: April 15, 2022

One former Wall Street darling that has been a serial underperformer during the greatest bull market of all time was the recipient of an upgrade Friday morning. That company is International Business Machines Corp, and it’s the PreMarket Prep Stock of the Day.

Long-Term IBM Price Action

IBM made its all-time high in February 2017 at $174.59. At the price of $129.50, it has a negative return of 26 percent. Over that same course of time, the S&P 500 index has yielded a positive return of 87 percent at 4,436.

Short-Term IBM Price Action

IBM bottomed on the same day (Feb. 24) as the S&P 500 index at $118.81. The recent high for the rebound ($133.08) was made one day after the index made its short top on March 30.

On Wednesday, the issue bottomed at $124.91 and rebounded to close at $126.14 and end a four-day losing streak.

Morgan Stanley’s IBM Upgrade

Before the open Thursday, Morgan Stanley analyst Erik Woodring upgraded the issue from Equal-Weight to Overweight and raised the price target from $147 to $150. The rating, equivalent to a Buy rating, is IBM’s first in almost two years.

It is not exactly a ringing endorsement of the company, but more or less identified the issue as a safe haven and one that is sporting a 5.1 percent dividend yield in a volatile investing environment. In other words, “a place to hide amid macroeconomic uncertainty.”

PreMarket Prep’s Take On IBM

When the issue was being covered on the show Thursday, it was trading at the $128.30 area.

Co-host Dennis Dick is mixed on the issue: “I am not shorting it, it has been a bit sleepy lately and media coverage of it could kickstart a rally.”

The author of this article emphasized clearing the premarket high ($129.80) and being able to remain in the $130 handle. If the issue went into retreat mode, there was potential support at the top of Wednesday’s range at $126.67.

By Joel Elconin

© 2022 The Epoch Times. The Epoch Times does not provide investment advice. All rights reserved.

Benzinga